We previously posted information regarding the novel anti-coagulant XARELTO (RIVAROXABAN) and the rise in adverse event reports coinciding with increased use of the blood thinner. We blogged about this during August 2014 in: “Xarelto Fatalities and Serious Side Effects” and explained why there were growing concerns and litigation was imminent. Later in August, we also explored the history behind the increase in market share, as well as FDA Letters questioning marketing practices use to catapult the drug to Blockbuster status in “Xarelto Fatalities, Deaths, Side Effects and Growing Market Share as Lawsuits Mount“. As expected, the rise in a link between side effects, reports of complications and ongoing investigations has drawn the attention of the manufacturer, lawyers and victims. Victims have come forward as awareness continues to grow about the dangers of complications and side effects.
The United States Judicial Panel on Multi-District Litigation (“JPML“), considered legal argument, and briefings, by Plaintiff’s that initiated cases, as well as the Defendants December 2014. On December 12, 2014, the JPML issued a Transfer Order centralizing all pending cases, as well as future cases, in MDL No. 2592, In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before the Honorable Eldon F. Fallon. The JPML Transfer Order is available here for viewing or download. This effectively consolidates the cases in a coordinated proceeding.
As summarized in the JPML Transfer Order, the court considered the Defendants arguments against centralization but was not persuaded. Rather, the JPML found that common questions of fact supported the centralization of parties and witnesses to promote the just and efficient administration of justice.
We anticipate that thousands of cases will ultimately be overseen in this newly formed MDL No. 2592, In re Xarelto (Rivaroxaban) Products Liability Litigation, as victims seek monetary damages for the death of loved ones or serious complications and injuries suffered through use of the blood thinner.
Our office continues to evaluate and investigate cases on behalf of families and victims from use of this product. Again as explored here, in “Xarelto Fatalities and Serious Side Effects” and here in “Xarelto Fatalities, Deaths, Side Effects and Growing Market Share as Lawsuits Mount“, the Blockbuster status the drug achieved comes in the wake of recent litigation over another novel anti-coagulant.
Click here for more content and periodical updates from Farmer Jaffe Weissing